Sign in
Taking people in NorwayPhase 4

Semaglutide with diet and online coaching for teens with obesity

Tests semaglutide injections plus diet and coaching in adolescents with obesity.

Key facts

Who runs it
Vestfold Hospital Trust
Where
Bergen, Bodo, Hammerfest, Oslo, Tonsberg, and Trondheim, NorwaySee the 6 sites
Registry title
eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)
Status
Recruiting
Phase
Phase 4
People taking part
220 people, planned
Started
28 Feb 2025
Expected to end
1 Mar 2027
Type of study
Interventional
Record updated
22 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers aged 12 to under 18 who want treatment for obesity and have tried to lose weight on their own before.

Age
12 years to under 18 years
Sex
Boys and girls can join.
Disease stage
Obesity with BMI of IOTF 35 kg/m2 or more, or BMI of IOTF 30 kg/m2 or more with at least one weight-related health problem, as judged by the treating doctor.
Earlier treatment
At least one self-reported unsuccessful diet attempt to lose weight.

Main reasons for not taking part

  • Not yet through puberty (Tanner stage 1), self-assessed
  • History of type 1 or type 2 diabetes
  • Intellectual disability, as judged by the investigator
  • Spoken Norwegian that is not good enough, as judged by the investigator

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Participants are eligible to be included in the study only if all of the following criteria apply: 1. Informed consent of parent(s) or legally authorized representative (LAR) of subject and assent of adolescent, as appropriate obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial 2. The trial participant must be above or equal to 12 years and below 18 years of age at the time of signing the informed consent. 3. Treatment seeking male and female adolescent patients with obesity (BMI ≥ IOTF 35 kg/m2) OR BMI ≥ IOTF 30 kg/m2 with at least one weight related comorbidity, risk factor or complication, as considered by the treating physician (44). 4. History of at least one self-reported unsuccessful dietary effort to lose body weight 5. Capable of giving signed informed consent as described in Appendix 3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol

Who cannot take part

  • Participants are excluded from the study if any of the following criteria apply: 1. Prepubertal patients (Tanner stage 1), self-assessed, see 8.2.1, table 1. 2. History of diabetes mellitus (type 1 or type 2) as judged by the investigator 3. Intellectual disability as judged by the investigator 4. Sub-optimal level of spoken Norwegian as judged by the investigator

Where in Norway

  • Helse Bergen HFBergen, NorwayTaking people
  • Nordlandssykehuset HFBodo, NorwayTaking people
  • Finnmarkssykehuset HFHammerfest, NorwayTaking people
  • Oslo University Hospital HFOslo, NorwayTaking people
  • Vestfold Hospital TrustTonsberg, NorwayTaking people
  • St. Olavs hospital HFTrondheim, NorwayTaking people

About the trial

What the trial wants to find out

To confirm superiority of once-weekly semaglutide s.c. 2.4 mg versus once-weekly semaglutide s.c. placebo, both as an adjunct to a 52-week blended face-to-face (F2F) and electronic behavioral therapy (eBT) program in treatment-seeking adolescents (12 to <18 years) with obesity on percentage reduction in body weight (% BMI change) [after completion of an initial 8-week blended F2F and electronic LED (eLED)].

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)
Plain-language title
Semaglutide with diet and online coaching for teens with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
22 September 2026